Professor, Division of Hem/Oncology, Samsung Medical Center

Speciality Interests

Gastric cancer, colorectal cancer, sarcoma, melanoma, others

Schedule

schedule of week
09 TUE
10
WEN
11
THU
12
FRI
13
MON
16
AM available available
PM

Medical School

2005 Ph.D. in Medicine Graduate School of Sungkyunkwan University, Korea 2002 Master of Science Graduate School of Sungkyunkwan University, Korea 1999 College of Medicine, Ewha Womans University, Korea

Specialty Training

Specialty Training
Fellowship   2004~2005 Clinical Fellowship in Hematology-Oncology, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Residency   2000~2003 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Internship   1999~2000 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Other Education

  • 2022~present Director Precision Oncology Center, Samsung Medical Center
    2019~present Director Experimental Therapeutics Development Center, Samsung Medical Center
    2019~2022 Member Member of Samsung Future Technology Meeting Committee, Korea
    2020~present Professor Department of Intelligence Precision Convergence Engineering, SKKU, Suwon
    2020~ Professor Division of Hem/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
    2014~2020 Associate Professor Division of Hem/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
    2010~2014 Assistant Professor Division of Hem/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
    2006~2010 Clinical Assistant Professor Division of Hem/Oncology, Samsung Medical Center
    2006~2008 Visiting Scientist Sidney Kimmel Cancer Center, San Diego, CA, USA
    2005.07 completed AACR Workshop in Cancer Research: Molecular Biology in Clinical Oncology
    2004.08 completed Australia and Asia Pacific Clinical Oncology Research Development Workshop: A Workshop in Effective Clinical Trials Design

Participation in Academic Societies
and Research

  • Present Member American Society of Clinical Oncology
    Present Member AACR
    Present Member Korean Association of Clinical Oncology

Thesis

EUR RADIOL 2021 10.1007/s00330-021-08094-3

Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer

Cha1, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D

CANCERS 2021 10.3390/cancers13102316

Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer

Kim1, JC; Heo, YJ; Kang, SY; Lee, J; Kim, KM

NATURE 2021 10.1038/s41586-021-03515-1

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Yen1, I; Shanahan, F; Lee, J; Hong, YS; Shin, SJ; Moore, AR; Sudhamsu, J; Chang, MT; Bae, I; Dela Cruz, D; Hunsaker, T; Klijn, C; Liau, NPD; Lin, E; Martin, SE; Modrusan, Z; Piskol, R; Segal, E; Venkatanarayan, A; Ye, X; Yin, JP; Zhang, LX; Kim, JS; Lim, HS; Kim, KP; Kim, YJ; Han, HS; Lee, SJ; Kim, ST; Jung, M; Hong, YH; Noh, YS; Choi, M; Han, O; Nowicka, M; Srinivasan, S; Yan, YB; Kim, TW; Malek, S

JAMA ONCOL 2021 10.1001/jamaoncol.2021.0275

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Chao1, JS; Fuchs, CS; Shitara, K; Tabernero, J; Muro, K; Van Cutsem, E; Bang, YJ; De Vita, F; Landers, G; Yen, CJ; Chau, I; Elme, A; Lee, J; Ozguroglu, M; Catenacci, D; Yoon, HH; Chen, ER; Adelberg, D; Shih, CS; Shah, SK; Bhagia, P; Wainberg, ZA

J DERMATOL 2021 10.1111/1346-8138.15824

Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center

Park1, JH; Yoon, D; Lee, J; Oh, SJ; Kim, HJ; Lee, JH; Lee, DY

CLOSE

Patients' Rights and Responsibilities

Patients' Rights

1. Right to receive medical care

Patients have the right to receive proper care in a safe setting without discrimination nor should their right to care be violated regardless of their gender, age, religion, social status, nationality, language, race, or physical/mental/financial status. Medical teams shall not refuse to provide care without justifiable reason.

2. Right to be informed and to make an autonomous decision

Patients have the right to obtain full and complete information from their medical team, to ask questions, and to determine their agreement or refusal concerning: diagnosis, treatment (purpose, plans and methods), outcomes of care (including unanticipated outcomes), discharge plan, participation in medical research studies, organ transplantation/donation, etc. Within ethical boundaries, patients may discontinue or refuse treatment, request that the medical team explain and suggest alternative treatments, and reserve the right to make their own decisions.

3. Right to confidentiality

Patients' rights to confidentiality regarding their physical/health status and privacy will not be violated. Patients can expect that all medical records/reports and their personal privacy will be kept confidential unless the patient has given consent or disclosure is permitted by law. To ensure their privacy, patients may be informed that Individuals not directly involved in their care may not be present and that the number of guardians accompanying patients to consultation rooms may be limited.

4. Right to request consultation and mediation

In the event of a medical dispute, patients may request consultation and mediation from an internal or external agency (Korea Consumer Agency, Korea Medical Dispute Mediation and Arbitration Agency).

5. Right to have values and beliefs respected

Patients will not be discriminated against because of their culture, religious values, or beliefs, and their rights will not be violated.

6. Right to receive care in a safe setting

Patients have the right to receive hospital-provided care where the patient’s medical information is protected and patient safety can be assured. In addition, patients have the right to be protected from possible dangers that can occur in a hospital and to have stability of mind and body.

Patients' Responsibilities

1. Responsibility to trust and respect the medical team

Patients must accurately inform the medical team of their health condition and must trust and respect the medical team's treatment plan. Patients may be responsible for consequences that result from not following instructions.

2. Responsibility to not use dishonest methods for medical treatment

Patients must reveal their identity before receiving any medical care and must not use false or dishonest methods, such as seeking medical care under disguised ownership.

3. Responsibility to abide by all hospital regulations

Patients are expected to treat all hospital staff and other patients with courtesy and respect; to abide by all hospital rules; and to earnestly fulfill their financial obligation to the hospital. Also, patients and their family members are expected to participate in all safety regulations.